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Retroviral transduction and expression of the human papillomavirus type 16 (HPV-16) E6 gene has been shown to activate
telomerase in human cervical and foreskin keratinocytes. There still remains some controversy, however, as to whether
expression of E6 in the context of the whole HPV-16 genome can activate telomerase. In this study, we have generated human
cervical keratinocyte clones that contain stably replicating HPV-16 episomes. Interestingly, the majority of the clones
exhibited low or no telomerase activity at early passage and this was associated with low transcript levels of the reverse
transcriptase component of telomerase, hTERT. The HPV-16-containing clones became immortal without a crisis and, at later
passage, exhibited elevated levels of telomerase and higher levels of hTERT without any apparent increase in HPV-16 copy
number, E6 transcript levels, or ability to degrade p53. These results indicate that HPV-16 by itself does not necessarily cause
telomerase activation in cervical keratinocytes, but rather, supports a model in which HPV-16 facilitates telomerase activationINTRODUCTION
Human papillomaviruses (HPVs) are causative agents
in the development of anogenital cancers, particularly
cervical cancer (Howley, 1991). The most common HPV
type associated with cervical cancer is HPV type 16
(HPV-16). The main transforming genes of HPV-16 and
other high-risk HPV types are E6 and E7. HPV-16 E7 is
capable of binding and inactivating the retinoblastoma
(Rb) tumor suppressor protein and Rb homologs (Dyson
et al., 1989). The best known function of HPV-16 E6 is the
targeting and degradation of the tumor suppressor pro-
tein, p53, through the ubiquitin pathway (Scheffner et al.,
1990, 1993; Werness et al., 1990). It has also been dem-
onstrated that E6 binds to a number of other cellular
proteins and has functions that are independent of p53
degradation (Rapp and Chen, 1998), including activation
of telomerase, a ribonucleoprotein complex that adds
telomeric repeats to the ends of chromosomes (Klin-
gelhutz et al., 1996). Expression of HPV-16 E6 and E7
efficiently immortalizes human anogenital keratinocytes,
the natural host cells of HPV-16 infection (Halbert et al.,
1992; Hawley-Nelson et al., 1989; Munger et al., 1989).
The use of E6 mutants has demonstrated that the ability
of E6 and E7 to immortalize cells is closely associated
1 To whom correspondence and reprint requests should be ad-247with the telomerase activating function of E6 (Kiyono et
al., 1998).
The precise mechanism of telomerase activation by
HPV-16 E6 is unknown. Regulation of telomerase activity
has been shown to occur through a number of processes
but, at minimum, involves up-regulation of the reverse
transcriptase component of telomerase, hTERT (Kilian et
al., 1997; Meyerson et al., 1997; Nakamura et al., 1997). It
has been demonstrated that E6 up-regulates the steady-
state levels of endogenous hTERT in keratinocytes (Oh et
al., 2001; Veldman et al., 2001). It has also been shown
that cotransfection of E6 with an hTERT promoter re-
porter construct can up-regulate transcriptional activity
(Gewin and Galloway, 2001; Oh et al., 2001; Veldman et
al., 2001), indicating that at least part of how E6 activates
telomerase is through up-regulation of hTERT transcrip-
tion. However, retroviral expression of E6, even in the
context of E7, does not activate telomerase at early
passage to levels comparable to those observed in later
passage HPV-16 E6/E7 immortalized cells, indicating ei-
ther that only a subpopulation of cells is susceptible to
telomerase activation by E6 or that E6 does not fully
activate telomerase to levels that are observed upon
complete immortalization (Klingelhutz et al., 1996). The
former hypothesis is supported by the observation that
not all keratinocyte clones that express HPV-16 E6 have
active telomerase (Klingelhutz et al., 1996). In addition,
levels of telomerase at early passage are quite hetero-in conjunction with other viral or cellular changes over tim
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with this heterogeneity, however, expression of E6 and
E7 together efficiently immortalizes keratinocytes and
the established immortal cell lines have high telomerase
(Kiyono et al., 1998).
Whether HPV-16 infection directly activates telomer-
ase in vivo is unclear. Most studies examining cervical
tissue or cervical cells from Pap smears indicate that
telomerase activation is common in high-grade cervical
intraepithelial neoplasias (CINs) and carcinomas (Nowak,
2000). Somewhat disparate results exist, however, regard-
ing whether telomerase activation is common in squa-
mous intraepithelial neoplasias (SILs) and low-grade
CINs, both of which are commonly associated with high-
risk HPV infection. Most studies indicate that significant
telomerase activation does not occur until lesions have
progressed to CINs (Nowak, 2000; Snijders et al., 1998).
Taken together, the in vitro and in vivo studies suggest
that HPV-16 infection and concomitant E6 expression are
closely associated with telomerase activation, but it is
unclear whether HPV infection by itself is sufficient for
telomerase activation. A significant problem in address-
ing this issue is that it has been difficult to infect kera-
tinocytes with HPV in vitro and to reproducibly generate
cells that carry stable HPV-16-replicating genomes. Sta-
ble replication of HPV episomes has been accomplished
by only a handful of laboratories (Flores et al., 1999;
Frattini et al., 1996; Meyers et al., 1997). In this study, we
have utilized a cloned HPV-16 construct (Flores et al.,
1999) to develop human cervical keratinocytes that con-
tain stably replicating HPV-16 episomes. Using this sys-
tem, we demonstrate that telomerase activation occurs
as a late, but common, event in the process of HPV-16
immortalization.
RESULTS
Generation of cells with HPV-16 episomes
To address the question of whether HPV-16 replication
is associated with telomerase activation, we utilized an
HPV-16 construct, pEFHPV-16W12E (a gift from Paul Lam-
bert), that has previously been shown to allow the com-
plete HPV life cycle in keratinocytes (Flores et al., 1999).
Normal human cervical keratinocytes were cotrans-
fected with recircularized HPV-16 genome and a G418
selectable marker, pLXSN. After selection in G418, colo-
nies of 200 cells or more were isolated by ring-cloning.
No colonies of any substantial size were detected in the
cells transfected with pLXSN alone. Eleven clones, A–K,
from plates cotransfected with HPV-16 and pLXSN were
picked and passaged in the presence of irradiated 3T3
feeders. Cells were collected at passage 5 (P5) for DNA
and telomerase analyses. The estimated minimum num-
ber of population doublings (pd) that the cells went
through at this point, if the colonies arose from a single
cell after transfection and the isolated colonies were 200
cells or more, would be greater than 25 pd. By Southern
blot analysis using undigested DNA, all of the clones
exhibited episomally replicating HPV-16 genomes in es-
timated copy numbers of 10 to 50 genomes (Fig. 1A). The
signal from the episomal band in the early passage
clones was greater than the signal obtained from a
subclone of W12E cells, the cell line from which the
original HPV-16 construct was obtained. Previous reports
have indicated that W12E cells contain up to 1000
HPV-16 copies/cell (Flores et al., 1999). The W12E sub-
clone used in our experiments was estimated to contain
only 10 HPV-16 copies per cell. The reason for this
difference is unknown. No HPV-16 episomes were de-
tected in the normal cervical cells that were used for
transfection (Fig. 1B, lane 1). The HPV-16-containing
clones continued to proliferate without an apparent cri-
sis, indicating that if events other than HPV-16 infection
were necessary for immortalization, they occurred with
relatively high frequency. To determine whether episomal
replication continued into later passage, the cells were
examined again at passage 22 (67 pds from single
cells). No consistent changes in HPV copy number or
episomal status were observed, although some of the
clones exhibited apparently lower episome copy num-
bers at later passage (Fig. 1B). The majority of the
clones, however, maintained copy numbers that were
similar to those observed at early passage, indicating
that episomal replication of HPV-16 was stable under
these culture conditions.
Telomerase activity in cells with episomally
replicating HPV-16
Because overexpression of HPV-16 E6 has been
shown to activate telomerase, we were interested in
determining whether telomerase was activated in the
context of episomally replicating HPV-16 genomes. The
11 independent HPV-16 containing clones were exam-
ined for telomerase activity by an ELISA-based assay at
both P5 and P22. Using this assay, the normal parental
cervical keratinocytes exhibited some but very low levels
of telomerase (Fig. 2). The majority of the HPV-16 con-
taining clones also exhibited low levels of telomerase
activity at early passage (Fig. 2). By passage 22, how-
ever, most of the clones had higher levels of telomerase,
comparable to a keratinocyte cell line transduced with
hTERT, the reverse transcriptase component of telomer-
ase. These results indicate that stable replication of
HPV-16 is insufficient for telomerase activation and that
other events may be necessary for inducing high levels
of telomerase activity.
hTERT and E6 expression in the HPV-16 containing
clones
Previous studies have shown that telomerase activity
in HPV-16 E6-expressing cells is correlated with higher
levels of hTERT transcription. One possible explanation
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for the above results was that hTERT transcription was
activated in the early passage cells but telomerase ac-
tivity was low for other reasons. Three clones (F, I, and K)
were chosen for examination of hTERT expression be-
cause they had low to no telomerase at early passage
but higher levels at later passage. Semiquantitative RT-
FIG. 1. Southern blot showing stably replicating HPV-16 episomes in cervical keratinocytes. (A) Lane 1, undigested DNA from the W12E-positive
control cell line; Lanes 2 to 12, undigested DNA from the HPV-16 clones at passage (P) 5; Lanes 13 to 15, BamHI-digested HPV-16 plasmid at indicated
concentrations. Thirty, ten, and three pg linearized DNA is estimated to represent approximately 5, 1.7, and 0.5 HPV-16 copies per cell (see Materials
and Methods). (B) Lane 1, undigested DNA from the normal parental cervical keratinocytes; Lane 2, undigested DNA from the SiHa cell line that
contains integrated HPV-16 DNA; Lane 3, undigested DNA from the W12E-positive control cell line that harbors episomal HPV-16 DNA; Lanes 4 to
14, undigested DNA from the HPV-16 clones at P22; Lanes 15 to 17, BamHI-digested HPV-16 plasmid at indicated concentrations.
FIG. 2. Results from TRAP assay measuring telomerase activity in normal cervical cells and early and late passage clones containing HPV-16
episomes. Values on the y-axis are absorbance units obtained from the ELISA-based telomerase assay analysis.
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PCR using primers that amplified hTERT and control
primers that amplified the housekeeping gene 36B4
were used to measure steady-state levels of hTERT in
the cells. Little to no hTERT was detected in the parental
normal cells. Similar to the telomerase activity, the later
passage clones exhibited an increase in hTERT levels as
compared to the early passage clones (Fig. 3), indicating
that there was a correlation between telomerase levels
and hTERT transcript levels in the early and later pas-
sage clones.
Because it has been demonstrated that overexpres-
sion of E6 activates telomerase, another possible expla-
nation for low levels of telomerase in the early passage
HPV-16 clones was that levels of E6 might be low at early
passage and increase as the cells are passaged in
culture. Because no reliable antibody exists for HPV-16
E6, we examined expression of E6 transcript by Northern
analysis. No differences in expression were observed in
the early and later passage clones (Fig. 4A), indicating
that increased telomerase was not associated with in-
creased E6 transcripts. To determine the functional sta-
tus of E6, we also examined p53 protein levels by West-
ern analysis in the three clones at early and later pas-
sage (Fig. 4B). Compared to normal keratinocytes, cells
that contained episomal copies of HPV-16 genomes
showed partial but incomplete degradation of p53. Im-
portantly, no differences between early and later pas-
sage clones were observed, indicating that the p53-
degradation function of E6 did not increase with passag-
ing or in association with telomerase activation.
DISCUSSION
Transcriptional up-regulation of hTERT has been
shown to be closely associated with activation of telo-
merase (Kilian et al., 1997; Meyerson et al., 1997; Naka-
mura et al., 1997). Several transcription factors and on-
cogenes have been implicated in activating hTERT tran-
scription, including c-myc, HPV-16 E6, Sp1, estrogen
receptor, and bcl-2 (Liu, 1999). It has been demonstrated
that other factors such as p21WAF/CIP, WT1, and Mad inhibit
hTERT transcription (Liu, 1999). Phosphorylation of the
hTERT protein has also been shown to be important in
telomerase activation (Kang et al., 1999; Li et al., 1997,
1998). Clearly, regulation of telomerase activity is com-
plex. In previous studies, it was demonstrated that ret-
roviral-mediated expression of HPV-16 E6 can up-regu-
late telomerase activity and transcription of hTERT
(Gewin and Galloway, 2001; Klingelhutz et al., 1996; Oh et
al., 2001; Veldman et al., 2001). The results presented
here indicate that stable replication of HPV-16 episomes
is insufficient for induction of high telomerase activity in
human cervical keratinocytes. Although the stable repli-
cation of HPV-16 episomes in cervical or foreskin kera-
tinocytes currently represents the best available model
to study HPV-16 infection, it is possible that HPV-16
infection in vivo may result in telomerase activation. It
seems unlikely that this is the case since most studies
indicate that early stage cervical lesions, lesions that
would be expected to contain high-risk HPV, contain little
or no telomerase activity (Nowak, 2000). Similarly, low or
no telomerase activity has been observed in early pas-
sage HPV-16-transfected cells in which the virus had
integrated into the cellular genome (Steenbergen et al.,
1996). These results raise the question as to whether
HPV-16 E6 expression in the context of the HPV genome
is sufficient for telomerase activation. As mentioned pre-
viously, high-level expression of E6 using retroviruses
FIG. 4. (A) Northern analysis for E6 transcripts. Lane 1, the normal
parental cervical cells; Lanes 2 and 3, clone F at P6 and P24; Lanes 4
and 5, clone I at P7 and P24; Lanes 6 and 7, clone K at P6 and P24. 36B4
is a housekeeping gene control. (B) Western analysis for p53 expres-
sion in the clones at early and later passages. Lane 1, normal keratin-
ocytes; Lanes 2 and 3, clone F at P6 and P24; Lanes 4 and 5, clone I
at P7 and P24; Lanes 6 and 7, clone K at P6 and P24. An antibody to
beta-actin was used as a control.
FIG. 3. Semiquantitative RT-PCR for hTERT expression in early and
later passage (P) HPV-16 clones. Lane 1, normal parental cervical cells;
Lanes 2 and 3, Clone F at P6 and P24; Lanes 4 and 5, Clone I at P7 and
P24; Lanes 6 and 7, Clone K at P6 and P24. The 36B4 housekeeping
gene was amplified using 25 cycles of PCR to avoid saturation,
whereas the hTERT gene was amplified using 40 cycles.
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does not always lead to telomerase activation in all
clones, suggesting that either another event occurs after
E6 expression to give rise to telomerase activation or
that telomerase activation by E6 occurs only in a subset
of certain cells. Another possibility is that telomerase
activation is only observed when E6 is expressed at very
high levels. In our studies, we did not observe an in-
crease in E6 transcript levels or an increase in p53
degradation as telomerase activity increased with pas-
saging. It is interesting to note that, in the context of
replicating HPV-16 genomes, low but detectable p53
protein was present in the cells, both at early and later
passage. Previous studies have indicated that cells that
express E6 from a retrovirus have little to no detectable
p53 (Klingelhutz et al., 1996). This raises the possibility
that E6 expression is lower in the context of the whole
HPV-16 genome than it is from a retroviral vector. These
lower levels might be insufficient to immediately activate
telomerase in the early passage cells but are sufficient to
augment telomerase activation over time. Another pos-
sibility is that later passage cells express different splice
forms of E6 that are better able to activate telomerase.
These possibilities need to be investigated further.
It has been demonstrated in cotransfection studies
that HPV-16 E6 can up-regulate transcription from hTERT
promoter constructs (Gewin and Galloway, 2001; Oh et
al., 2001; Veldman et al., 2001). For example, it was
shown that up-regulation of the hTERT promoter by E6 is
dependent on the E boxes and Sp1-binding sites in the
promoter region but is independent of up-regulation of
c-myc (Gewin and Galloway, 2001; Oh et al., 2001). These
cotransfection studies indicate that expression of E6 by
itself can activate the hTERT promoter when the pro-
moter is introduced as a plasmid. It is possible that
activation from the endogenous promoter is more com-
plex. Thus, the “naked” promoter might be easily induced
by E6, but the endogenous promoter could require
changes in chromatin structure that are not present in all
cells or that occur over time in the presence of E6
expression. These changes could be the result of an-
other unidentified alteration that affects chromatin struc-
ture. Indeed, it has been demonstrated that alterations in
chromatin structure affect expression of hTERT (Cong
and Bacchetti, 2000; Takakura et al., 2001). This model
would explain the observation that there is an increase
in telomerase expression over time in E6-containing
cells and the observation that not all cells that express
E6 have active telomerase. It would be interesting to
further examine this possibility by determining the profile
of the hTERT promoter in early and later passage cells
with regard to histone acetylation and other factors that
might play a role in chromatin structure.
In summary, our results indicate that stable replication
of HPV-16 episomes is insufficient to activate telomerase
in adult cervical cells. However, HPV-16 may augment
telomerase activation over time. It is likely that this acti-
vation plays a role in the development of HPV-16-asso-
ciated malignancies. Whether HPV-16 associated telom-
erase activation plays a role in the viral life cycle or viral
persistence remains to be determined.
MATERIALS AND METHODS
Cell culture and generation of HPV-16 clones
The 7905 base pair (bp) clone pEFHPV-16W12E (gift
from Dr. Paul F. Lambert, University of Wisconsin Medical
School, Madison, WI) derived from an HPV-positive pa-
tient was utilized as the HPV-16 genome for our replica-
tion assays (Flores et al., 1999). One hundred micro-
grams of HPV-16 genomes was digested overnight in a
750-l reaction from the pUC19 vector using the restric-
tion enzyme BamHI followed by heat inactivation of the
enzyme. The entire digested DNA was then re-ligated in
a large volume of 36 ml by addition of T4 DNA ligase to
the reaction mixture. This reaction was incubated over-
night in a cold room (4°C) and purified using a Qiagen-tip
500 column (Qiagen DNA Maxi Kit) with buffers recom-
mended by the manufacturer. After elution, the DNA was
precipitated by addition of isopropanol and centrifuga-
tion 15,000 g for 2 h at 4°C. The pellet was washed with
70% ethanol and centrifuged 15,000 g for an additional 30
min at 4°C, air-dried, and resuspended in 200 l TE (10
mM Tris–Cl pH 7.6 and 1 mM Na2EDTA).
Primary human cervical keratinocytes (HCKs) derived
from tissue obtained from a hysterectomy performed for
endometriosis were cultured on irradiated J2 3T3 fibro-
blast feeders in E-media (Wu et al., 1982). Cells were
passaged 1:4 when they were 70 to 80% confluent. For
transfections, irradiated J2 3T3 fibroblast feeders were
removed differentially by short trypsin treatment, wash-
ing with PBS, and resupplementing with E media. The
next day, these plates were transfected with the ligated
HPV-16 episomes. For the transfections, Effectene (Qia-
gen) reagent was used according to the manufacturer’s
instructions. Briefly, 3 g of re-ligated DNA was mixed
with EC buffer to a final volume of 300 l. A 29-l aliquot
of Enhancer reagent was added and mixed by vortexing.
The reaction mix was incubated for 5 min at room tem-
perature and 36 l of Effectene reagent added and vor-
texed. The reaction was incubated 10 min at room tem-
perature. Cell-culture plates were washed with 1 PBS
and 7 ml of fresh media added. Three milliliters of media
without serum was added to the transfection mixture,
mixed gently, and added to the plates. HCK-transfected
plates were incubated at 37°C overnight in 5% CO2. The
following day (day 2) the media were removed from these
plates and replaced with fresh E-media. Irradiated J2 3T3
fibroblast feeders were also added to each plate. In
addition, the -galactosidase control plate was X-gal
stained to control for transfection efficiency which was
estimated to be from 5 to 10%. On day 3, each transfected
plate was split into four 100-mm plates containing irra-
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diated J2 3T3 feeder cells. These plates were incubated
overnight as stated above before addition of 200 g/ml
G418 on day 4. Selective pressure was maintained for
approximately 15–20 days before visible colonies were
evident and large enough for isolation. Irradiated feeders
were added weekly. Individual colonies were ring-iso-
lated when they reached a diameter of at least 0.5 cm
and passaged to one well of a six-well tissue culture dish
containing irradiated feeders. When they became conflu-
ent, the cells were passaged with irradiated feeders onto
a 60-mm tissue culture plate and designated as passage
2 (P2). The cells were then passaged onto a 100-mm
culture plate (P3) and then serially passaged 1:4 onto
100-mm culture plates using irradiated feeders.
Telomerase PCR ELISA assay
Feeder cells were removed by differential trypsiniza-
tion before collection of HCKs for the telomere repeat
amplification protocol (TRAP) assay. After removal of the
HCKs by further trypsinization, the trypsin was inhibited
by addition of PBS with 2% FBS. Immediately following
mixing of the cells, an aliquot was removed and cells
were counted using a hemacytometer. Aliquots of 2 
105 cells were spun and washed in PBS. The supernatant
was removed and the pellets were frozen at 80°C.
Samples were analyzed using the Roche Telomerase
PCR ELISA assay according to the manufacturer’s in-
structions. Samples were lysed in the provided buffer
and 1000 cell equivalents per reaction were used for the
subsequent TRAP assay. One-tenth of the reaction was
used for ELISA detection. A cell line expressing the
telomerase rate-limiting RNA subunit, hTERT, was used
as a positive control in this experiment. Lysis buffer (1 l)
from the reaction kit was used starting at the PCR reac-
tion as a negative control.
Southern analysis
DNA was isolated from 100-mm tissue culture plates
(approximately 70% confluent). J2 3T3 fibroblasts were
differentially trypsinized off each plate. The QIAamp DNA
Blood Mini Kit (Qiagen) was utilized for DNA isolation
according to the manufacturer’s instructions. Isolated
DNA was analyzed by Southern blot. To detect viral
episomes 2 g of uncut DNA from each clone was run on
a 1% TBE (Tris–Borate–EDTA) agarose gel. The HPV-16
clone pEFHPV-16WI2E was digested with BamHI. Linear-
ized BamHI-cut HPV-16 was isolated for a control using
the Qiagen Gel Extraction Kit. Amounts of 30, 10, and 3
pg of linearized HPV-16 were run in addition to the clones
to provide standards to determine viral episome levels.
Control linear DNA, since it was being used at low
concentrations, was stabilized in 100 ng/l calf thymus
DNA. Uncut DNA from the W12E cell line (Flores et al.,
1999) was used as a control for presence of viral epi-
somes. Normal DNA from the parental cervical cells was
used as a negative control. SiHa cells, containing only
integrated DNA, were also used as a control. Gels were
run until the loading dye was approximately 12 cm into
the gel. To transfer, the DNA was depurinated in 0.25 M
HCl for 30 min. The gel was then Southern blotted onto
Hybond-N membrane (Amersham Pharmacia Biotech)
using 0.4 M NaOH overnight. The membrane was re-
moved from the transfer apparatus and soaked in 2
SSC for 10 min. The membrane was allowed to dry a few
minutes and then prepared for prehybridization. The
membrane was prehybridized in 12 ml 68°C 10 SSC for
25 min. An aliquot of 120 l (10 mg/ml) of denatured
salmon sperm was then added to 12 ml of 68°C prehy-
bridization buffer (50 ml: 5 ml 50 Denhardt’s, 15 ml 20
SSC, 5 ml 10% SDS, 25 ml dH2O, 10% 5 g dextran sulfate).
Poured off the membrane was 10 SSC and pre-hybrid-
ization buffer plus salmon sperm was added and incu-
bated in a rotating 68°C oven for 4 h.
The HPV-16 probe was made using primers that am-
plified three regions of the HPV-16 genome. Probe A
primer pair 23,144, HPV-16 nucleotides 6226–6250 (GGA
TGG TGA TAT GGT TCA TAC TGG C), and 20,962, nucle-
otides 858–838 (GCC GGA TCC TTA TGG TTT CTG AGA
ACA GAT), amplify a region of HPV-16 approximately
2.538 kb. Probe B primer pair 23,145, nucleotides 6000–
5977 (GGA TGG CCA CTA ATG CCC ACA CCT), and
22,934, nucleotides 4471–4492 (CCT CCC ACA GCT ACA
GAT ACA C), amplify a 1.529-kb region of HPV-16. Probe
C primer pair 22,936, nucleotides 5320–5299 (TAA TAG
AAG TAG GTG GGC TGC), and 20,225, nucleotides 3441–
3458 (CGA GGC CTG GGC ACC GAA GAA ACA C),
amplify a 1.879-kb region of HPV-16. To amplify HPV-16
probes, linearized HPV-16 was utilized in the PCR reac-
tion. A 100-l PCR reaction included 10 l 10 PCR Gold
Buffer, 6 l 25 mM MgCl2, linear HPV-16 (20 ng), individ-
ual primer pairs (20 pmol of each), 2 l of 10 mM dNTPs,
2 l AmpliTaq Gold (5 U/l), and dH2O to a final volume
of 100 l. Each primer set was used to amplify one
probe, and products were isolated by running the entire
PCR product on a 1% TAE agarose gel and extracting the
DNA using the Qiagen gel extraction kit. The probes
were then mixed at a concentration ratio of (probe A,
2.5:probe B, 1.5:probe C, 1.9).
Radiolabeled HPV-16 oligonucleotides were made us-
ing the Roche random primed DNA labeling kit according
to the manufacturer’s instructions. [-32P]dCTP and
[-32P]dATP radioisotopes were utilized in the reaction to
make labeled probe. Labeled probe was purified using a
Sephadex Nick column (Amersham Pharmacia Biotech
AB). On each membrane 1.5 million cpm/ml were used.
The probe was denatured at 100°C for 10 min in salmon
sperm DNA and added to the membrane containing
fresh 68°C prehybridization buffer with salmon sperm
DNA. The membrane was incubated at 68°C overnight in
the rotating hybridization oven. The membrane was
washed two times with 50 ml of 68°C wash buffer (1%
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SDS, 2 SSC) for 1 h each, followed by a 30-min wash
with 50 ml of 68°C wash buffer, and exposed to Kodak
X-OMAT AR film. Estimation of episomal copy number
was based on the calculation that 30, 10, and 3 pg cut
HPV-16 represents approximately 3  106, 1  106, and
3  105 HPV genomes, respectively, and that 2 g
genomic DNA represents approximately 600,000 cells.
Thus, 30, 10, and 3 pg of cut HPV-16 would represent
approximately 5, 1.7, and 0.5 copies/cell, respectively.
Northern analysis
Total RNA was isolated cells that were 70% confluent
using TRIReagent (Molecular Research Center Inc., Cin-
cinnatti, OH) according to the manufacturer’s protocol.
Before isolation the irradiated feeders were differentially
removed with trypsin. Thirty micrograms of total RNA
was separated on a 1.2% agarose–6% formaldehyde de-
naturing gel. The RNA was transferred by capillary action
to Zeta-Probe Membrane (Bio-Rad Laboratories, Her-
cules, CA). After transfer, the membrane was UV cross-
linked and prehybridized in 50% formamide, 5 Den-
hardt’s reagent, 5 SSC, 20 mM NaH2PO4 pH 6.5, 0.1%
SDS, and 200 g/ml salmon sperm DNA at 42°C for 4 h.
Probe DNAs were radiolabeled with [-32P]dATP (3000
Ci/mmol) randomly primed using HotPrime DNA Label-
ing Kit (GenHunter Corp., Nashville, TN). Probes were
purified using NICK Columns (Pharmacia Biotech, Pisca-
taway, NJ). The 16 E6 probe was a 424-bp fragment of
pLXSN-16E6 obtained from digestion of the plasmid with
AflIII and the 36B4 probe (both constructs were gift from
Denise Galloway) was digested out of pGEM5. After
labeling, the 16E6 probe was added to hybridization
buffer at 1  106 counts/ml and allowed to hybridize
overnight at 42°C. The membrane was washed twice
with 5 SCC and three times with 0.1 SSC, 0.1% SDS
for 30 min at 60°C, and then exposed to film at 80°C.
The membrane was then stripped and hybridization was
performed using the 36B4 probe at 1  105 counts/ml.
The membrane was washed similarly to that done after
16E6 hybridization and exposed to film.
RT-PCR and Western blots
Total RNA was isolated using TRIReagent as de-
scribed above. cDNA synthesis reactions were per-
formed using Ambion’s RETROscript kit (Ambion, Inc.,
Austin, TX). Two-microgram samples of total RNA were
used as the template for single-stranded cDNA synthesis
reactions primed with the random decamers included in
the RETROscript kit. PCR reactions were performed us-
ing one-twentieth of each reverse-transcription reaction
with primers for both the hTERT and the 36B4. The
primers for hTERT and the acidic ribosomal protein P0
gene, 36B4 (also called RPLP0), a housekeeping gene,
have been described (Bieche et al., 2000; Nakamura et
al., 1997). Twenty-five cycles of PCR were used for am-
plification of 36B4 and 40 cycles for hTERT to yield
products of 150 and 144 base pairs, respectively. These
PCR cycle numbers have been shown to circumvent
saturation or plateau effect and allow for semiquantita-
tive comparison of expression of hTERT and 36B4 be-
tween different samples (Bieche et al., 2000 and data not
shown). Amplified products were run on 2% agarose gels
and visualized using ethidium bromide staining and UV
transillumination.
Western blots were performed as described using 40
g protein per lane (Kiyono et al., 1998). A Primary
antibody for p53 (Ab 6, Oncogene Research) and a sec-
ondary goat anti-mouse horseradish-peroxidase (HRP)
conjugated antibody (Jackson ImmunoResearch Labs,
Inc.) were used for detection of p53 protein, whereas a
primary antibody for beta-actin (I-19, Santa Cruz) and a
secondary donkey anti-goat HRP conjugated antibody
(Santa Cruz) were used for detection of beta-actin pro-
tein. Chemiluminescent detection was performed using
a Renaissance chemiluminescence detection kit NEN
Life Science Products) and X-Omat film (Kodak).
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